Clinical trials
Early Breast Cancer clinical trials
Below are recruiting early breast cancer clinical trials, each written for real people, not researchers. We’re tracking 430 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06817525RecruitingPhase 2
Chemo and immunotherapy before surgery for early triple-negative breast cancer
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
Zhengzhou, HenanAges 18–65 - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT06966700RecruitingPhase 3
Study of Sac-TMT in Early High-Risk Breast Cancer
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT06430541RecruitingPhase 1
Psilocybin therapy for fear of cancer recurrence
This trial tests if psilocybin-assisted therapy can help reduce the intense worry that cancer might come back. It is for people who have finished their main treatments for early-stage breast cancer or advanced ovarian cancer.
Aurora, ColoradoAges 21 years+ - NCT07178171RecruitingPhase 1
QL1706 + short chemo for early triple-negative breast cancer
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
Xi'an, ShaanxiAges 18–70 - NCT06078384RecruitingPhase 2
Pembrolizumab and chemo for early-stage triple-negative breast cancer
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
AmiensAges 18 years+ - NCT05723250Recruiting
Rural early cancer care coaching and education program
This study tests an educational “care coordination” program to help people living in rural Vermont manage care during the early stages of breast, lung, or colon cancer treatment. It may help you feel more supported and organized while starting or preparing for chemotherapy.
Burlington, VermontAges 18 years+ - NCT04141462Recruiting
Genetic testing study for early cancer risk
This study looks at whether DNA (from a tumor or related samples) can help identify inherited cancer risk in people who develop cancer at a young age. It may help families learn more about risk factors and guide future screening or prevention.
BesançonAges 18 years+ - NCT06318507Recruiting
Gut Bacteria and Immunotherapy for Triple-Negative Breast Cancer
This study looks at how bacteria in your gut might affect the way your body responds to immunotherapy for triple-negative breast cancer. It focuses on women who are overweight or obese and are about to start treatment with pembrolizumab before surgery.
Baton Rouge, LouisianaAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT05673018Recruiting
Galleri blood test study in Medicare patients
This study looks at how a blood test called Galleri (and also how it compares when people have not yet had it) works for older adults with Medicare. It may help find whether the test can improve cancer detection or follow-up for people who are not already in urgent cancer workups.
Fort Smith, ArkansasAges 50 years+ - NCT04710797Recruiting
Lymph node surgery for early-stage ovarian cancer
This trial studies whether removing (dissecting) lymph nodes during surgery can improve care for people with early-stage ovarian cancer that still needs chemotherapy. You may be eligible if you have certain ovarian cancer types and your scans and surgery do not show clearly suspicious lymph nodes.
Guangzhou, GuangdongAges 18–70 - NCT07427186Recruiting
Studying how immunotherapy affects the immune system in early-stage cancer
This trial looks at how your immune system responds to immunotherapy given before surgery for early-stage solid tumors (like lung, head and neck, melanoma, or bladder cancer). The goal is to understand why some people respond better, so doctors can improve treatment for future patients.
ToulouseAges 18 years+ - NCT06627712RecruitingPhase 3
SBRT with immunotherapy and chemo for early-stage triple-negative breast cancer
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
Sichuan, ChengduAges 18–65 - NCT06598046RecruitingPhase 2
Utidelone and Capecitabine for triple-negative breast cancer brain metastases
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Zhengzhou, HenanAges 18 years+ - NCT07806266Recruiting
Developing a questionnaire for women with metastatic breast cancer
This study is developing a questionnaire to better understand the experiences of women with metastatic breast cancer. It involves completing questionnaires and possibly interviews to help improve care and support for others with this condition.
GhentAges 18 years+ - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT04845828Recruiting
Sentinel node biopsy versus full node removal in early uterine cancer
This study compares two ways to check lymph nodes during surgery for early-stage endometrial (uterine) cancer: sentinel node biopsy versus removing more lymph nodes. It may help find whether the less extensive approach can stage the cancer accurately with fewer side effects.
SeoulAges 20–80 - NCT06493019RecruitingPhase 2
Pembrolizumab with chemo and radiation for early anal cancer
This trial tests a combination of the immunotherapy drug pembrolizumab, two chemotherapy drugs (carboplatin and paclitaxel), and radiation for people with early-stage anal cancer who cannot take the usual chemotherapy. The goal is to see if this approach is safe and effective as an alternative treatment.
Indianapolis, IndianaAges 18 years+ - NCT06455124RecruitingPhase 2
Short radiation and chemo-immunotherapy for early rectal cancer after local surgery
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
ShanghaiAges 18–75 - NCT04476485Recruiting
Predicting breast cancer recurrence after extended hormone therapy
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
Harbin, HeilongjiangAges 18–70 - NCT05219695RecruitingPhase 1
Ultrasound imaging and treatment for breast tumors
This study uses focused ultrasound waves to create detailed images of breast tumors and deliver targeted treatment. It aims to improve how breast tumors are treated while minimizing damage to healthy tissue.
New York, New YorkAges 18 years+ - NCT06450171Recruiting
Multi-cancer early detection test for people at high risk
This study tests a blood-based multi-cancer early detection (MCED) screening test in people with a high risk of cancer due to inherited gene changes or strong family history. The goal is to see if this test can find cancer early.
Boston, MassachusettsAges 22 years+ - NCT06789653Recruiting
Using age-related proteins in early breast cancer
This study is testing a new way to use proteins in your blood that change with age to better understand early-stage breast cancer. It may help doctors personalize your care.
Chapel Hill, North CarolinaAges 22–66
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for early breast cancer?
- Yes. Clin2 currently lists 430 recruiting early breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a early breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a early breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.